Last reviewed · How we verify
Probiotic plus lactulose
Probiotics restore beneficial gut bacteria while lactulose acts as a prebiotic osmotic laxative to promote bowel regularity and support gastrointestinal health.
Probiotics restore beneficial gut bacteria while lactulose acts as a prebiotic osmotic laxative to promote bowel regularity and support gastrointestinal health. Used for Constipation and irregular bowel movements, Gastrointestinal dysbiosis and microbiome imbalance, Digestive health support.
At a glance
| Generic name | Probiotic plus lactulose |
|---|---|
| Also known as | Ecotec plus Duphalac |
| Sponsor | Qurratul Ain Jamil |
| Drug class | Probiotic + prebiotic combination |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Probiotics introduce live beneficial microorganisms (typically Lactobacillus and Bifidobacterium species) to restore healthy gut flora, while lactulose, a non-absorbable disaccharide, increases stool bulk and osmotic pressure to promote bowel movements. Together, they work synergistically to improve intestinal function, enhance nutrient absorption, and support the gut microbiome balance.
Approved indications
- Constipation and irregular bowel movements
- Gastrointestinal dysbiosis and microbiome imbalance
- Digestive health support
Common side effects
- Bloating
- Flatulence
- Abdominal discomfort
- Diarrhea (from lactulose)
Key clinical trials
- Effect of Probiotic on Gut Microbiota in Young Children With Functional Constipation (PHASE2)
- A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy. (PHASE4)
- The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms (NA)
- Effect of Lactobacillus DSM17938+ on Functional Constipation and Intestinal Flora in Pregnant Women (NA)
- Synbiotics Interventions for Managing Cirrhosis and Its Complications (PHASE4)
- Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy (NA)
- Characteristic of Intestinal Flora in Male Elderly With Small Intestinal Bacterial Overgrowth
- Effects of Activia in IBS (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probiotic plus lactulose CI brief — competitive landscape report
- Probiotic plus lactulose updates RSS · CI watch RSS
- Qurratul Ain Jamil portfolio CI